Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + sintilimab vs donafenib + sintilimab for first-line advanced hepatocellular carcinoma with Child-Pugh B liver function
ChiCTR2300076242Phase 3Not yet recruiting
- Sponsor
- Beijing Ditan Hospital
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of lenvatinib, donafenib and sintilimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing Ditan Hospital. Primary endpoint: time to progression. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
lenvatinibdonafenibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300076242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076242.